Live Chat Software

Five Key Considerations for Early Access Programmes

Five Key Considerations for Early Access Programmes

Embarking on an Early Access Programme is challenging due to a number of factors, including navigating the complex regulatory landscape and the modality of providing access to patients. Ahead of her participation in the upcoming Early and Managed Access Programmes Forum, we spoke exclusively to Allison Morgan, Managing Director, Metis Clinical to discuss the key considerations that need to be taken prior to initiating an early access programme. 

This article will discuss: defining the nature of supply, considering the stage of drug development, anticipating for demand, planning for data capture restrictions and ethical considerations


Please note: That all fields marked with an asterisk (*) are required.